Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) traded down 3.4% during trading on Monday . The stock traded as low as $0.75 and last traded at $0.75. 17,282 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 60,503 shares. The stock had previously closed at $0.78.
Iterum Therapeutics Trading Down 3.4 %
The company has a debt-to-equity ratio of 1.64, a quick ratio of 4.40 and a current ratio of 4.40. The company has a 50-day simple moving average of $0.98 and a 200 day simple moving average of $1.05. The company has a market capitalization of $9.82 million, a P/E ratio of -0.17 and a beta of 1.59.
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.15). Sell-side analysts expect that Iterum Therapeutics plc will post -3.54 earnings per share for the current year.
Institutional Trading of Iterum Therapeutics
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
- Five stocks we like better than Iterum Therapeutics
- Insider Trading – What You Need to Know
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in E-Commerce: A Guide
- 5 Reasons Mullen Automotive is About to Turn a Corner
- What Are Dividend Achievers? An Introduction
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.